

# CONSOLIDATED DEVELOPMENT PIPELINE BY PHASE



	PHASE 3 (6 NMEs + 26 LCMs)				FILED (1 NMEs + 3 LCMs)	
<b>ONCOLOGY</b>	<p>★ <b>EXKIVITY®</b> 1L NSCLC EGFR exon 20</p> <p>★ <b>NINLARO®</b> Maint. ND MM no SCT (US, EU, CN)</p>	<p><b>ICLUSIG®</b> FL Ph+ ALL (US)</p> <p>★ <b>NINLARO®</b> Maint. ND MM post-SCT (US, EU)</p>	<p><b>CABOMETYX®</b> mCRPC combo w/atezolizumab (JP)</p> <p><b>ZEJULA®</b> Breast cancer (JP)</p>	<p><b>CABOMETYX®</b> 2L mNSCLC combo w/atezolizumab (JP)</p> <p><b>relugolix</b> Prostate cancer (JP, CN)</p>		
<b>RARE GENETICS &amp; HEMATOLOGY</b>	<p>★ <b>TAK-755</b> cTTP</p> <p><b>ADYNOVATE®</b> recombinant Factor VIII Pediatric Hema (EU)</p>	<p>★ <b>pabinafusp alfa</b> Hunter Syndrome</p> <p>★ <b>TAKHZYRO®</b> HAE pediatric</p>	<p>★ <b>LIVTENCITY®</b> 1L CMV infect. in HSCT</p> <p>★ <b>TAKHZYRO®</b> BMA</p>	<p>★ <b>LIVTENCITY®</b> Post-transplant CMV infect. (JP)</p> <p>★ <b>VONVENDI®</b> vWD Adult Prophylaxis (EU, CN)</p>	<p>★ <b>OBIZUR®</b> Recomb antihemophilic factor porcine (JP)</p> <p>★ <b>VONVENDI®</b> vWD peds on-demand &amp; surgery</p>	<p><b>OBIZUR®</b> Recomb antihemophilic factor porcine (CN)</p>
<b>NEUROSCIENCE</b>	<p>★ <b>soticlestat</b> DS</p>	<p>★ <b>soticlestat</b> LGS</p>				
<b>GASTRO-ENTEROLOGY</b>	<p><b>ENTYVIO®</b> SC CD (US, JP)</p> <p><b>ENTYVIO®</b> Pediatric UC</p>	<p>★ <b>ENTYVIO®</b> GvHD Prophylaxis</p> <p><b>ENTYVIO®</b> Pediatric CD</p>	<p>★ <b>ALOFISEL®</b> Perianal Fistulas in CD (US)</p> <p><b>VOCINTI®</b> <i>H. Pylori</i> (CN)</p>	<p>★ <b>ALOFISEL®</b> Pediatric perianal Fistulas in CD</p>		
<b>PDT</b>	<p><b>CUVITRU®</b> PID (JP)</p> <p><b>TAK-880</b> IgG – Low IgA</p>	<p>★ <b>HYQVIA®</b> CIDP (US, EU)</p> <p><b>Prothromplex</b> DOAC Reversal<sup>1</sup></p>	<p>★ <b>HYQVIA®</b> CIDP, MMN (JP)</p> <p><b>HYQVIA®</b> PID (JP)</p>		<p><b>HYQVIA®</b> HyHub AVA Device (US)</p> <p>★ <b>HYQVIA®</b> Pediatric PID (US)</p>	
<b>VACCINES</b>	<p><b>Nuvaxovid®</b> COVID-19 Vaccine Booster (JP)</p>				<p><b>TAK-003</b> Dengue Vaccine (EU + endemic countries)</p>	

1. Study actively recruiting  
Status as of July 28, 2022 and is subject to change. Table is not comprehensive. For full glossary of abbreviations please refer to appendix.

★ Orphan Drug Designation potential (in any region / indication for a given asset)

# CONSOLIDATED DEVELOPMENT PIPELINE BY PHASE



	PHASE 1 (19 NMEs + 2 LCMs)					PHASE 2 (14 NMEs + 2 LCMs)		
ONCOLOGY	TAK-102 Solid tumors	TAK-103 Solid tumors	TAK-186 EGFR Solid Tumor <sup>2</sup>	TAK-940 CD19+ hematologic malignancies	★ modakafusp alfa Solid tumors	★ modakafusp alfa R/R MM	★ subasumstat Multiple cancers	★ TAK-007 CD19+ hematologic malignancies <sup>1</sup>
	TAK-500 Solid tumors	TAK-676 Solid tumors	TAK-280 B7-H3 Solid Tumor <sup>2</sup>	NEW ICLUSIG® Pediatric Ph+ ALL				
RARE GENETICS & HEMATOLOGY	★ TAK-755 SCD	★ mezagitamab IgAN <sup>1</sup> , MM				★ mezagitamab MG, ITP	★ TAK-611 MLD (IT)	★ TAK-755 iTTP
	NATPARA® Hypoparathyroidism (JP)							
NEUROSCIENCE	★ TAK-861 NT1	TAK-341 Parkinson's Disease	★ TAK-925 Post-op/anesthesia	★ TAK-594 Frontotemporal dementia <sup>2</sup>		TAK-071 Parkinson's Disease	TAK-041 Anhedonia in MDD	TAK-653 Inadequate resp. in MDD
GASTRO-ENTEROLOGY	TAK-062 Celiac Disease	TAK-510 Nausea & vomiting	TAK-105 Nausea & vomiting	sibofimloc Luminal Crohn's Disease		TAK-101 Celiac Disease	TAK-954 POGD	★ fazirsiran AATD-Associated Liver Disease
						TAK-951 Nausea & vomiting	sibofimloc Crohn's Disease (Post-op Ileitis)	
PDT						CEPROTIN® SC PCD (JP)	TAK-881 Immunodeficiencies	
VACCINES	TAK-426 Zika Vaccine							

1. Study actively recruiting

2. Currently in phase 1 of a phase 1/2 trial

Status as of July 28, 2022 and is subject to change. Table is not comprehensive. For full glossary of abbreviations please refer to appendix.

NEW Added to clinical development since last quarter

★ Orphan Drug Designation potential (in any region / indication for a given asset)

NME

LCM

# GLOSSARY OF ABBREVIATIONS



## Regional Abbreviations:

CN: China; EU: Europe; JP: Japan; US: United States of America

<b>AATD</b>	α1-antitrypsin deficiency
<b>ADC</b>	antibody drug conjugate
<b>ADHD</b>	attention deficit hyperactivity disorder
<b>AHA</b>	acquired hemophilia A
<b>ALK</b>	anaplastic lymphoma kinase
<b>ALCL</b>	anaplastic large-cell lymphoma
<b>ALL</b>	acute lymphocytic leukemia
<b>AML</b>	acute myeloid leukemia
<b>ASCT</b>	autologous stem cell transplant
<b>ARD</b>	acid-related diseases
<b>AVA</b>	Advanced Vial Access
<b>BBB</b>	blood brain barrier
<b>BLA</b>	biologics license application
<b>BMA</b>	bradykinin mediated angioedema
<b>BTD</b>	breakthrough therapy designation
<b>CAR-T</b>	chimeric antigen receptor-T
<b>CD</b>	Crohn's disease
<b>CHMP</b>	Committee for Medicinal Products for Human Use
<b>CIDP</b>	chronic inflammatory demyelinating polyradiculoneuropathy
<b>CLL</b>	chronic lymphocytic leukemia
<b>CML</b>	chronic myeloid leukemia
<b>CMV</b>	cytomegalovirus
<b>CNS</b>	central nervous system
<b>CPF</b>	complex perianal fistulas
<b>CRL</b>	complete response letter
<b>CRPC</b>	Castrate-resistant prostate cancer
<b>CTCL</b>	cutaneous T-cell lymphoma
<b>cTTP</b>	congenital thrombotic thrombocytopenic purpura
<b>DEE</b>	developmental and epileptic encephalopathies
<b>DLBCL</b>	diffuse large B-cell lymphoma

<b>DOAC</b>	direct oral anti-coagulation
<b>DS</b>	Dravet syndrome
<b>DU</b>	duodenal ulcer
<b>Dx</b>	Diagnosis
<b>EE H</b>	erosive esophagitis healing
<b>EE M</b>	erosive esophagitis maintenance
<b>EGFR</b>	epidermal growth factor receptor
<b>EMA</b>	European Medicines Agency
<b>FDA</b>	the U.S. Food & Drug Administration
<b>FL</b>	front line
<b>FSI</b>	first subject in
<b>FY</b>	fiscal year
<b>GERD</b>	gastroesophageal reflux disease
<b>GI</b>	gastrointestinal
<b>GU</b>	gastric ulcer
<b>GvHD</b>	graft versus host disease
<b>HAE</b>	hereditary angioedema
<b>H2H</b>	head-to-head
<b>HemA</b>	hemophilia A
<b>HL</b>	Hodgkin lymphoma
<b>HSCT</b>	hematopoietic stem cell transplant
<b>IBD</b>	inflammatory bowel disease
<b>IgAN</b>	immunoglobulin A nephropathy
<b>IH</b>	idiopathic hypersomnia
<b>INCAT</b>	Inflammatory Neuropathy Cause and Treatment disability score
<b>IND</b>	investigational new drug
<b>iNHL</b>	indolent non-Hodgkin's lymphoma
<b>ITP</b>	Immune thrombocytopenic purpura
<b>iTTP</b>	immune thrombotic thrombocytopenic purpura
<b>IV</b>	intravenous
<b>iPSC</b>	induced pluripotent stem cells
<b>L-ASA</b>	low dose aspirin

<b>LSD</b>	lysosomal storage disorder
<b>LCM</b>	lifecycle management
<b>LGS</b>	Lennox-Gastaut syndrome
<b>mAb</b>	monoclonal antibody
<b>MAOB</b>	monoamine oxidase B
<b>MDD</b>	major depressive disorder
<b>MG</b>	myasthenia gravis
<b>MLD</b>	metachromatic leukodystrophy
<b>MM</b>	multiple myeloma
<b>MMN</b>	multifocal motor neuropathy
<b>NBE</b>	New Biological Entity
<b>NCE</b>	New Chemical Entity
<b>ND</b>	newly diagnosed
<b>NDA</b>	new drug application
<b>Neg</b>	Negative
<b>NERD</b>	non-erosive reflux disease
<b>NHL</b>	non-Hodgkin lymphoma
<b>NK</b>	natural killer
<b>NME</b>	new molecular entity
<b>NMPA</b>	National Medical Products Administration
<b>NSCLC</b>	non-small cell lung cancer
<b>NSCT</b>	non stem cell transplant
<b>NT1 or 2</b>	narcolepsy Type 1 or 2
<b>ORR</b>	overall response rate
<b>OSA</b>	obstructive sleep apnea
<b>PARP</b>	poly (ADP-ribose) polymerase
<b>PAS</b>	prior approval supplement
<b>PCAB</b>	potassium competitive acid blocker
<b>PCD</b>	protein C deficiency
<b>PEX</b>	plasma exchange
<b>Ph+ ALL</b>	Philadelphia chromosome-positive acute lymphoblastic leukemia

<b>PID</b>	primary immunodeficiency
<b>PK</b>	pharmacokinetics
<b>PMDA</b>	Japan's Pharmaceuticals and Medical Devices Agency
<b>POC</b>	proof of concept
<b>POGD</b>	post-operative gastrointestinal dysfunction
<b>PONV</b>	postoperative nausea and vomiting
<b>PRIME</b>	Priority medicines scheme by EMA
<b>PTCL</b>	peripheral T-cell lymphoma
<b>PTH</b>	parathyroid hormone
<b>R/R</b>	relapsed/refractory
<b>RCC</b>	renal cell cancer
<b>RTK</b>	receptor tyrosine kinase
<b>RTU</b>	ready to use
<b>sALCL</b>	systemic anaplastic large cell lymphoma
<b>SBS</b>	short bowel syndrome
<b>SC</b>	subcutaneous formulation
<b>SCD</b>	sickle cell disease
<b>SCT</b>	stem cell transplant
<b>SID</b>	secondary immunodeficiency
<b>SLE</b>	systemic lupus erythematosus
<b>sq</b>	squamous
<b>STING</b>	stimulator of interferon genes
<b>SUMO</b>	small ubiquitin-related modifier
<b>TCE</b>	T-cell engager
<b>TESD</b>	treatment emergent sexual dysfunction
<b>TKI</b>	tyrosine kinase inhibitor
<b>UC</b>	ulcerative colitis
<b>VCD</b>	virologically confirmed dengue
<b>vWD</b>	von Willebrand disease
<b>VWF</b>	von Willebrand factor